Dr. Benjamin Leder
Dr. Leder is a clinical investigator and practicing physician whose medical practice and research focuses on osteoporosis and other metabolic bone diseases. Dr. Leder is a graduate of Yale University and Harvard Medical School and completed his Internal Medicine Residency and Endocrine Fellowship at Massachusetts General Hospital where he has remained ever since. He is currently an Associate Professor of Medicine at Harvard Medical School and the Medical Director of the Massachusetts General Hospital Endocrine Unit’s clinical practice. Dr. Leder’s early work helped define an independent role of estrogens in regulating skeletal metabolism in men and he has continued to investigate the relative roles of these androgens and estrogens in bone and other organ systems. More recently, his group has explored new strategies to optimize the efficacy of combination anabolic and antiresorptive therapy in postmenopausal osteoporosis. Specific, he leads the ongoing Denosumab and Teriparatide Administration (DATA) studies that have demonstrated that combining an anabolic agent (teriparatide) with the RANKL inhibitor, denosumab, stimulates greater increases in bone density and bone quality by inhibiting teriparatide-induced bone resorption while stimulating modeling-based bone formation. These studies have additionally demonstrated that the initial use of an anabolic agent followed by an antiresorptive agent results in much larger increases in bone mass and more structurally sound skeletal microarchitecture as compared to using these drugs in the opposite order. Dr. Leder has authored many original papers, chapters and reviews and was inducted in to the American Society for Clinical Investigation (ASCI) in 2011. He currently chairs the Professional Practice Committee of the American Society of Bone and Mineral Research where he has focused on developing strategies to combat the growing word-wide gap in osteoporosis diagnosis and treatment.
